Role of radiotherapy and chemotherapy in the risk of secondary leukaemia after a solid tumour in childhood

European Journal of Cancer

Volumn 42, Issue 16, 2006, Pages 2757-2764

  Haddy, Nadia ^a   Cécile Le Deley, Marie ^a,b   Samand, Akhtar ^a,b   Diallo, Ibrahima ^a,b   Guérin, Sylvie ^a   Guibout, Catherine ^a   Oberlin, Odile ^b   Hawkins, Mike ^c   Zucker, Jean Michel ^d   de Vathaire, Florent ^a  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d INSTITUT CURIE   (France)

Author keywords

Chemotherapy; Childhood; Leukaemia; Radiation; Second cancer

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; EPIPODOPHYLLOTOXIN DERIVATIVE; PLATINUM COMPLEX; TOXIN; VINCA ALKALOID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEPHROBLASTOMA; NEUROBLASTOMA; OSTEOSARCOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RISK ASSESSMENT; SOLID TUMOR;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGIC METHODS; FRANCE; GREAT BRITAIN; HUMANS; LEUKEMIA; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY;

EID: 33750084415     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.05.034     Document Type: Article

References (39)

1. Tucker M.A., D'Angio G.J., Boice Jr. J.D., et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 317 (1987) 588-593
2. de Vathaire F., Francois P., Hill C., et al. Role of radiotherapy and chemotherapy in the risk of second malignant neoplasms after cancer in childhood. Br J Cancer 59 (1989) 792-796
3. de Vathaire F., Hawkins M., Campbell S., et al. Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment. Br J Cancer 79 (1999) 1884-1893
4. Hawkins M.M., Wilson L.M., Stovall M.A., et al. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukemia after childhood cancer. BMJ 304 (1992) 951-958
5. Hawkins M.M., Wilson L.M., Burton H.S., et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 88 (1996) 270-278
6. Cohen R.J., Curtis R.E., Inskip P.D., et al. The risk of developing second cancers among survivors of childhood soft tissue sarcoma. Cancer 103 (2005) 2391-2396
7. Kony S.J., de Vathaire F., Chompret A., et al. Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. Lancet 350 (1997) 91-95
8. Travis L.B., Curtis R.E., Stovall M., et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 86 (1994) 1450-1457
9. Greco F.A., Johnson D.H., and Hainsworth J.D. Chronic oral etoposide. Cancer 67 suppl 1 (1991) 303-309
10. Davidson A., Gowing R., Lowis S., et al. Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG). Eur J Cancer 33 (1997) 1816-1822
11. Le Deley M.C., Leblanc T., Shamsaldin A., et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 21 (2003) 1074-1081
12. Preston D.L., Kusumi S., Tomonaga M., et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 137 (1994) S68-S97
13. Major I.R., and Mole R.H. Myeloid leukemia in X-ray irradiated CBA mice. Nature 272 (1978) 455-456
14. Mole R.H., Papworth D.G., and Corp M.J. The dose-response for X-ray induction of myeloid leukemia in male CBA/H mice. Br J Cancer 47 (1983) 285-291
15. Boice Jr. J.D., Blettner M., Kleinerman R.A., et al. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst 79 (1987) 1295-1311
16. Curtis R.E., Boice Jr. J.D., Stovall M., et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 25 (1992) 1745-1751
17. Travis L.B., Andersson M., Gospodarowicz M., et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92 (2000) 1165-1171
18. Kramarova E., and Stiller C.A. The international classification of childhood cancer. Int J Cancer 68 (1996) 759-765
19. Percy C., Fritz A., Jack A., et al. International classification of the diseases for oncology. third edition (2000), WHO, Geneva ICD-O-3
20. Grimaud E., Shamsaldin A., Lamon A., et al. Programme original de calcul de dose appliqué à l'étude de seconds cancers. Bull Cancer Radiother 81 (1994) 482
21. Diallo I., Lamon A., Shamsaldin A., et al. Estimation of the radiation dose delivered at any point in the body for individual patients in external beam radiotherapy. Radiother Oncol 38 (1996) 269-271
22. Shamsaldin A., Grimaud E., Hardiman C., et al. Dose distribution throughout the body from radiotherapy for Hodgkin's disease in childhood. Radiother Oncol 49 (1998) 85-90
23. Cristy M. Active bone marrow distribution as a function of age in humans. Phys Med Biol 26 (1981) 389-400
24. Menegoz F., and Cherié-Challine L. Le cancer en France: incidence et mortalité. Situation en 1995. Evolution entre 1975 et 1995 (2000), Reseau FRANCIM, Paris
25. Office for National Statistics. Cancer 1971-1997 CDROM. London: ONS; 1999.
26. Breslow N.E., and Day N.E. Statistical methods in cancer research Volume II - the design and analysis of cohort studies (1987), International Agency for Research on Cancer, Lyon
27. Venzon D.J., and Moolgavkar S.H. A method for computing profile-likelihood-based confidence intervals. Appl Statist 37 (1988) 87-94
28. Preston D.L., Lubin J.H., and Pierce D.A. EPICURE User's guide (1993), HiroSoft International Corp., Seattle, WA
29. Hawkins M.M. Second primary tumors following radiotherapy for childhood cancer. Int J Radiat Oncol Biol Phys 19 (1990) 1297-1301
30. Olsen J.H., Garwicz S., Hertz H., et al. Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries. BMJ 307 (1993) 1030-1036
31. Neglia J.P., Friedman D.L., Yasui Y., et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 93 (2001) 618-629
32. Devereux S., Selassie T.G., Vaughan Hudson G., et al. Leukemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation. BMJ 301 (1990) 1077-1080
33. Salvagno L., Simonato L., Soraru M., et al. Secondary leukemia following treatment for Hodgkin's disease. Tumori 79 (1993) 103-107
34. Hahn P., Nelson N., and Baral E. Leukemia in patients with breast cancer following adjuvant chemotherapy and/or postoperative radiation therapy. Acta Oncol 33 (1994) 599-602
35. Travis L.B., Holowaty E.J., Bergfeldt K., et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 340 (1999) 351-357
36. Garwicz S., Anderson H., Olsen J.H., et al. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer 88 (2000) 672-678
37. UNSCEAR. Sources and effects of ionizing radiation. New York, NY: United Nations; 2000.
38. Curtis R.E., Boice Jr. J.D., Stovall M., et al. Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. J Natl Cancer Inst 86 (1994) 1315-1324
39. Harrison C.N., Gregory W., Hudson G.V., et al. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Br J Cancer 81 (1999) 476-483